PERTH, AUSTRALIA: November 21, 2011 – Phylogica Ltd (ASX: PYC, XETRA:PH7), a leading Australian peptide drug discovery company, announced today the progression of its collaboration with MedImmune, the worldwide biologics unit of AstraZeneca, to develop novel antibiotics.
For further information please download PDF below:
